The week's transactions tell a clear story: China-origin assets now command 32% of global licensing deal value, up from 21% just two years ago. This structural shift reflects years of R&D investment now yielding differentiated clinical-stage assets that global pharma cannot replicate internally. Antibody-

Biotech valuation hinges on a small number of binary clinical events. A Phase 3 readout. An FDA approval letter. A manufacturing inspection that either passes or doesn't. These go/no-go moments create the fundamental tension in pharmaceutical M&A: buyers and sellers often agree on everything

In my November 25 post, I discussed "Royalties as a Credit Derivative," exploring how creative financing can extend a biotech's runway without diluting equity. Oberland Capital is the real-world practitioner of that theory – a specialist fund that doesn't just bet on biotech outcomes,

Dayra Therapeutics is a Toronto-based biotech company developing oral macrocyclic peptide drugs for immunological diseases. The company launched in November 2025 with approximately $70 million in committed funding, comprising a $50 million upfront payment from Biogen and a $20 million equity commitment from Versant Ventures. The company emerged from

The pharmaceutical royalty market has grown at a 45% CAGR since 2018, reaching over $6 billion in annual transaction volume—yet sophisticated investors operate almost entirely without the insurance and reinsurance tools that other asset classes take for granted. This gap creates both significant risk management challenges and potential opportunities

A stage-by-stage decision framework for evaluating synthetic royalties, royalty monetization, and alternatives in the $29 billion royalty financing market Pharmaceutical royalty financing has transformed from a niche instrument into a $29.4 billion market (2020–2024), more than double the preceding five years. But the critical question isn&

How outcome-based payment models are forcing royalty investors to rethink fundamental valuation assumptions—and what the early data reveals High-cost gene therapies are ushering in revolutionary one-time treatments—often with price tags in the millions—but they are also forcing a rethink of how payments (and by

Biotech Transactions: November 23-29, 2025 GE HealthCare's $2.3 billion acquisition of Intelerad dominated a shortened Thanksgiving week that still managed to produce meaningful deal flow. Fifteen transactions closed or were announced within the seven-day window, representing over $2.7 billion in disclosed value. November 24

Despite a 73% collapse in venture funding from $15.7B (2021) to $4.2B (2024), China's clinical trial registrations reached unprecedented levels in 2024-2025. The country logged 4,900 clinical trials in 2024—a 13.9% increase year-over-year—and by mid-2025 had nominally surpassed

RA Capital Management, the $12.6 billion biotech-focused investment firm founded in 2001, has aggressively expanded beyond its equity roots into pharmaceutical royalty financing, launching a Structured Capital Solutions platform in September 2024 that positions the firm as an integrated capital provider across the full biopharma lifecycle. This strategic